JPH056559B2 - - Google Patents

Info

Publication number
JPH056559B2
JPH056559B2 JP58039146A JP3914683A JPH056559B2 JP H056559 B2 JPH056559 B2 JP H056559B2 JP 58039146 A JP58039146 A JP 58039146A JP 3914683 A JP3914683 A JP 3914683A JP H056559 B2 JPH056559 B2 JP H056559B2
Authority
JP
Japan
Prior art keywords
csf
stability
stable
inhibitor
inactivated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP58039146A
Other languages
English (en)
Japanese (ja)
Other versions
JPS59166089A (ja
Inventor
Masayoshi Ono
Kunitake Hirashima
Masami Betsusho
Ikuo Imazeki
Hitoshi Nomura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Priority to JP58039146A priority Critical patent/JPS59166089A/ja
Priority to EP84102620A priority patent/EP0118908A3/en
Publication of JPS59166089A publication Critical patent/JPS59166089A/ja
Publication of JPH056559B2 publication Critical patent/JPH056559B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP58039146A 1983-03-11 1983-03-11 Ｃｓｆ抑制物質 Granted JPS59166089A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP58039146A JPS59166089A (ja) 1983-03-11 1983-03-11 Ｃｓｆ抑制物質
EP84102620A EP0118908A3 (en) 1983-03-11 1984-03-09 Csf inhibitory substance

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP58039146A JPS59166089A (ja) 1983-03-11 1983-03-11 Ｃｓｆ抑制物質

Publications (2)

Publication Number Publication Date
JPS59166089A JPS59166089A (ja) 1984-09-19
JPH056559B2 true JPH056559B2 (online.php) 1993-01-26

Family

ID=12544964

Family Applications (1)

Application Number Title Priority Date Filing Date
JP58039146A Granted JPS59166089A (ja) 1983-03-11 1983-03-11 Ｃｓｆ抑制物質

Country Status (2)

Country Link
EP (1) EP0118908A3 (online.php)
JP (1) JPS59166089A (online.php)

Also Published As

Publication number Publication date
JPS59166089A (ja) 1984-09-19
EP0118908A2 (en) 1984-09-19
EP0118908A3 (en) 1987-05-06

Similar Documents

Publication Publication Date Title
Saklatvala et al. Purification to homogeneity of pig leucocyte catabolin, a protein that causes cartilage resorption in vitro
Mizel Studies on the purification and structure-function relationships of murine lymphocyte activating factor (interleukin 1)
JP2562192B2 (ja) 血清アルブミンの純化方法
JP2509407B2 (ja) 生物学的に活性な化合物の単離方法
HU196832B (en) Process for separating plasma proteins from cell cultures
JPH0381290A (ja) 精製されたアルブミン溶液の製造方法
JPH05500602A (ja) 微生物学的に生成されたキモシンの回収方法
Lappin et al. Monocyte C1‐inhibitor synthesis in patients with C1‐inhibitor deficiency
Chaga et al. Isolation and characterization of catalase from Penicillium chrysogenum
Krystal et al. CM Affi‐Gel Blue chromatography of human urine: a simple one‐step procedure for obtaining erythropoietin suitable for in vitro erythropoietic progenitor assays
Malhotra Purification and characterization of dicoumarol-induced prothrombins. III. Alumina pH 4.6 atypical (2-Gla)+ variant
Echetebu et al. Multiple forms of human y-glutamyltransferase
Bassett Large scale preparation of wheat germ agglutinin
Prydz Studtes on Proconvertin (Factor VII) II. Purification
Larsson et al. Characterization of a human mitogenic factor (MF) released by phytohemagglutinin-activated lymphocytes
JPS62244441A (ja) 抗体固定化担体
JPS6226226A (ja) 抗腫瘍性ポリペプチド
RU2048521C1 (ru) Способ получения полипептида со свойствами лимфотоксина человека
US7365173B2 (en) Method for the production of pure virally inactivated butyrylcholinesterase
JPH022390A (ja) 新規なヒト顆粒球マクロファージコロニー刺激因子
Mazitsos et al. Designed chimaeric galactosyl–mimodye ligands for the purification of Pseudomonas fluorescens β-galactose dehydrogenase
JPH0361440B2 (online.php)
Slavik et al. [101] Purification of thymidylate synthetase from enzyme-poor sources by affinity chromatography
JPS59166089A (ja) Ｃｓｆ抑制物質
SU767121A1 (ru) Способ выделени и очистки трипсина и химотрипсина